CNS Pharmaceuticals
CNSP
8 hedge funds and large institutions have $222K invested in CNS Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 7 closing their positions.
3.5% more ownership
Funds ownership: 0.78% → 4.28% (+3.5%)
27% less funds holding
Funds holding: 11 → 8 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
47% less capital invested
Capital invested by funds: $422K → $222K (-$200K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$113K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$63.1K |
| 3 |
Morgan Stanley
New York
|
+$225 |
| 4 |
Citigroup
New York
|
+$16 |
| 5 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$335K |
| 2 |
VF
Virtu Financial
New York
|
-$19K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$14.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$12.9K |
| 5 |
HF
HRT Financial
New York
|
-$8K |
CNSP Hedge Fund Activity: Q3 2025 in Review
8 institutional investors reported a position in CNS Pharmaceuticals (CNSP) for Q3 2025, worth a combined $222K — down 47% from $422K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CNSP and 4 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was DRW Securities, opening a new position worth an estimated $113K. The largest seller was Armistice Capital, exiting entirely with an estimated $335K sold.
- 8 institutional investors held CNS Pharmaceuticals (CNSP) as of Q3 2025, down from 11 in Q2 2025.
- Funds reported $222K of CNS Pharmaceuticals stock for Q3 2025, down 47% quarter-over-quarter.
- 4 funds opened new CNS Pharmaceuticals positions in Q3 2025 and 7 closed out, a net change of -3 holders.
- The largest CNS Pharmaceuticals buyer in Q3 2025 was DRW Securities, an estimated $113K added.
- The largest CNS Pharmaceuticals seller in Q3 2025 was Armistice Capital, an estimated $335K sold.
Based on aggregated 13F filings for Q3 2025.